Table 3 Comparison between IPM response and response to previous cytokine therapy
From: IPM chemotherapy in cytokine refractory renal cell cancer
Cytokines | ||||
IFN monotherapy | 24 | |||
IFN combination therapy | 9 | |||
Median interval cytokines to commencing IPM | 5.9 months | (1–62) | ||
Cytokines | IPM | |||
Response | ||||
Adjuvant | 1 | 0 | ||
PR | 1 | 1 | ||
MR | 3 | 8 | ||
SD | 11 | 9 | ||
PD | 15 | 13 | ||
NE | 2 | 2 | ||
PR or better | One out of 30 (3%) | One out of 31 (3%) | ||
SD or better | 15 out of 30 (50%) | 18 out of 31 (58%) | ||
Symptomatic | ||||
Response | Six out of 25 (24%) | 17 out of 28 (61%) | ||
Median progression-free interval | ||||
Overall | 3.9 months | 4.4 months | ||
(a) SD or better | 10.2 months | 6.9 months | ||
(b) PD | 2.4 months | 1.9 months | ||
P-value (a vs b) | <0.001 | <0.001 | ||
(c) Symptomatic response | 10.2 months | 6.2 months | ||
(d) No symptomatic response | 3.7 months | 1.8 months | ||
P-value (c vs d) | 0.09 | <0.001 | ||
Symptomatic response to cytokines vs IPM | Cytokine symptomatic response | |||
No | Yes | Total | ||
IPM symptomatic response | No | 4 | 1 | 5 |
Yes | 11 | 5 | 16 | |
Total | 15 | 6 | 21 | |
